Jason Segal

The market makes noise. I tell the story. ASX life sciences companies explained.

The Pulse Check

Feb 20, 2026

•

10 min read

The Three-Day Market Update

Jason Segal

The Pulse Check

The Price of Buying Time: The Adherium (ASX: ADR) Story

Feb 17, 2026

•

12 min read

The Price of Buying Time: The Adherium (ASX: ADR) Story

Jason Segal

Clarity Pharmaceuticals (ASX: CU6)

Feb 16, 2026

•

13 min read

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Jason Segal

The Pulse Check

Feb 13, 2026

•

10 min read

Why do stocks fall on good news

Jason Segal

The Pulse Check

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Feb 12, 2026

•

11 min read

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Jason Segal

The Pulse Check

Why I'm not catching the CSL falling knife

Feb 11, 2026

•

8 min read

Why I'm not catching the CSL falling knife

Jason Segal

The Pulse Check

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Feb 10, 2026

•

12 min read

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Jason Segal

The Pulse Check

Why fundamental analysis doesn't work for Biotech Stocks

Feb 9, 2026

•

8 min read

Why fundamental analysis doesn't work for Biotech Stocks

Jason Segal

The Pulse Check

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

Feb 6, 2026

•

11 min read

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

Jason Segal

The Pulse Check

Feb 5, 2026

•

9 min read

How medtech survives the SaaSpocolypes

Jason Segal

The Pulse Check

How the analysts separate signal from noise

Feb 4, 2026

•

13 min read

How the analysts separate signal from noise

Jason Segal

Starpharma (ASX:SPL)

The Platform Was the Prize: Starpharma’s 25-Year Pivot

Feb 3, 2026

•

12 min read

The Platform Was the Prize: Starpharma’s 25-Year Pivot

Jason Segal

The Pulse Check

The Cannabis Merger Trade: Liquidity First, Value Later

Jan 16, 2026

•

11 min read

The Cannabis Merger Trade: Liquidity First, Value Later

Jason Segal

The Pulse Check

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jan 15, 2026

•

11 min read

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jason Segal

The Pulse Check

Jan 14, 2026

•

7 min read

The Art of the Capital Raise

Jason Segal

The Pulse Check

The Problem With Being the Best Stock in the Market

Jan 13, 2026

•

9 min read

The Problem With Being the Best Stock in the Market

Jason Segal

The Pulse Check

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jan 12, 2026

•

9 min read

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jason Segal

The Pulse Check

Biotech’s biggest week starts as the M&A window opens

Jan 9, 2026

•

7 min read

Biotech’s biggest week starts as the M&A window opens

Jason Segal

The Pulse Check

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jan 8, 2026

•

8 min read

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jason Segal

The Pulse Check

What does it mean to be a "platform technology"?

Jan 7, 2026

•

5 min read

What does it mean to be a "platform technology"?

Jason Segal

Noxopharm (ASX: NOX)

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Jan 6, 2026

•

9 min read

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Jason Segal

The Pulse Check

Day #1: The Biotech 165 Challenge Begins

Jan 5, 2026

•

13 min read

Day #1: The Biotech 165 Challenge Begins

Jason Segal

The Pulse Check

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Dec 19, 2025

•

11 min read

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Jason Segal

The Pulse Check

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Putting ASX Healthcare in the Hot Seat in 2026

Jason Segal

The Pulse Check

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

Same Result. Two Markets. Very Different Answers.

Jason Segal